News Archive 2009

18 Jun, 2009
Innocoll Announces Provisional Findings from its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections

Innocoll Announces Provisional Findings from its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections.

More
31 Mar, 2009
Innocoll, Inc. Files 510 (k) application for CollaRx Lidocaine Sponge

Innocoll, Inc. Files 510 (k) application for CollaRx Lidocaine Sponge

ASHBURN, Va., March 31, 2009 /PRNewswire/ — Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, has filed a US 510k application for its CollaRx™ Lidocaine Sponge for the management of painful wounds. 

More
19 Mar, 2009
Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients

ASHBURN, Va., March 19, 2009 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the second of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections.

More
16 Mar, 2009
Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients

ASHBURN, Va.,March 16, 2009 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of two ongoing U.S. phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx® GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections.

More